Comparing Gavreto vs Retevmo
| Gavreto (pralsetinib) | Retevmo (selpercatinib) |
|
|---|
| Gavreto (pralsetinib) | Retevmo (selpercatinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Non Small Cell Lung Cancer, Thyroid Cancer. Gavreto may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Thyroid Cancer, Non Small Cell Lung Cancer, Solid Tumors. Retevmo may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Gavreto (pralsetinib) | More about Retevmo (selpercatinib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Be the first to share your experience with this drug. |
Retevmo has an average rating of 10.0 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Gavreto side effects |
View all Retevmo side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Gavreto prices |
View all Retevmo prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
22.2 hours |
32 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 714 drugs are known to interact with Gavreto:
|
A total of 629 drugs are known to interact with Retevmo:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
September 04, 2020 |
May 08, 2020 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Armour Thyroid
Armour Thyroid is used for hashimoto's disease, hypothyroidism, after thyroid removal, thyroid ...
Tagrisso
Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose ...
NP Thyroid
NP Thyroid is used for hashimoto's disease, hypothyroidism, after thyroid removal, thyroid cancer ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.